// App-Quantinova.ai

270 : Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Researchers

Presenter

  • Sumanta K. Pal

Principal Investigators

  • Ian Murchie Thompson

  • Naomi B. Haas

  • Daniel J. George

  • Daniel Yick Chin Heng

  • Brian M. Shuch

  • Mark N. Stein

  • Maria S. Tretiakova

  • Peter Humphrey

  • Adebowale Adeniran

  • Vivek Narayan

  • Georg A. Bjarnason

  • Ulka N. Vaishampayan

  • Ajjai Shivaram Alva

  • Tian Zhang

  • Scott Wesley Cole

  • Melissa Plets

  • John Wright

  • Primo "Lucky" N. Lara

Medical Centers

  • SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Christus Santa Rosa Medical Center Hospital, Houson, TX

  • Abramson Cancer Center, University of Pennsylvania (ECOG-ACRIN), Philadelphia, PA

  • Duke University Medical Center, Durham, NC

  • Department of Radiation Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

  • UCLA Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA

  • Columbia University Medical Center, New York, NY

  • University of Washington, Seattle, WA

  • Yale University, New Haven, CT

  • University of Pennsylvania, Philadelphia, PA

  • Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

  • University of Michigan, Ann Arbor, MI

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • Oklahoma Cancer Specialists and Research Institute, Tulsa, OK

  • National Cancer Institute, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD

  • UC Davis Comprehensive Cancer Center, Sacramento, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Savolitinib

  • Crizotinib

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02761057

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved